Combination Therapy for Early Neurodegenerative Disease Intervention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases, such as Alzheimer's disease, are ineffective in early stages when amyloid β peptides have not caused irreversible brain damage, and there is a need for medications that can effectively treat these diseases before clinical expression.
Innovation Solution
A pharmaceutical combination of an insulin sensitizer, such as a thiazolidinedione derivative, and a lipid metabolism modulator, such as an agonist of thyroid hormone receptor, is administered to target different signaling pathways synergistically to reduce amyloid β peptide accumulation and visceral adiposity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single drug therapy is used, then treatment simplicity is maintained, but therapeutic effectiveness is insufficient for neurodegenerative diseases
Solution Approach 1:
The patent combines two drugs with different mechanisms of action (insulin sensitizer and lipid metabolism modulator) into a single pharmaceutical composition. This merging approach achieves synergistic therapeutic effects against neurodegenerative diseases while managing treatment complexity through formulation integration.
Solution Approach 2:
The pharmaceutical composition is designed to simultaneously target multiple pathological pathways involved in neurodegenerative diseases, including amyloid-beta clearance, lipid metabolism regulation, and insulin sensitivity improvement. This multi-functionality allows a single treatment to address multiple disease mechanisms.
2Loss of time
If early therapeutic intervention is implemented, then disease progression can be delayed, but effective medications are currently unavailable for pre-clinical stages
Solution Approach 1:
The patent enables preliminary therapeutic action by providing a pharmaceutical composition that can be administered in pre-clinical and early clinical stages of neurodegenerative diseases. The combination therapy is designed to prevent and delay disease progression before irreversible brain damage occurs, allowing intervention at optimal therapeutic windows.
3Reliability
If drug combination targeting multiple pathways is used, then synergistic therapeutic effect is achieved, but dosing complexity increases
Solution Approach 1:
The patent merges multiple drugs into a single pharmaceutical composition with fixed dosing ratios. This approach maintains the synergistic therapeutic effects of combination therapy while simplifying administration to a single dose, thereby improving dosing convenience and patient compliance.
Data Source
AI summary
Provided is a pharmaceutical combination for preventing or treating a neurodegenerative disease. The pharmaceutical combination includes a first agent being an insulin sensitizer and a second agent being a lipid metabolism modulator. Also provided is a method for preventing or treating a neurodegenerative disease in a subject in need thereof by administering the first agent and the second agent to the subject, thereby reducing the visceral adiposity and the accumulation of amyloid β peptides in the subject.